Clinical trials in Parkinson’s disease have tested vitamin D3 doses ranging from 1,000 to 1,200 IU per day, with the best-known trial using 1,200 IU daily for 12 months. There’s no official Parkinson’s-specific dosage, but the evidence points toward maintaining blood levels of 75 to 100 nmol/L (30 to 40 ng/mL) for the best outcomes. Getting there usually requires somewhere between 1,000 and 4,000 IU per day, depending on how deficient you are to start.
Why Vitamin D Matters in Parkinson’s
The brain region that breaks down in Parkinson’s, the substantia nigra, has unusually high concentrations of both vitamin D receptors and the enzyme that converts vitamin D into its active form. This means the cells that produce dopamine are especially sensitive to vitamin D status. In lab studies, vitamin D’s active form increases the activity of tyrosine hydroxylase, the enzyme responsible for making dopamine, and protects dopamine-producing neurons against damage from oxidative stress in a dose-dependent way.
People with Parkinson’s are also far more likely to be deficient. A study published in JAMA Neurology found that 55% of Parkinson’s patients had insufficient vitamin D levels (at or below 30 ng/mL), compared to 36% of healthy controls. Full deficiency, defined as below 20 ng/mL, affected 23% of Parkinson’s patients versus just 10% of controls.
The Blood Level That Appears Optimal
A large analysis using over two decades of data from the National Health and Nutrition Examination Survey found a U-shaped relationship between vitamin D blood levels and mortality in Parkinson’s patients. The lowest risk of death occurred at a blood level of approximately 78.68 nmol/L (about 31 ng/mL), and patients whose levels fell between 75 and 100 nmol/L (30 to 40 ng/mL) had the highest survival rates. Levels below 50 nmol/L were linked to worse outcomes, but so were levels above 100 nmol/L, meaning more is not necessarily better.
This target range of 75 to 100 nmol/L is consistent with what’s generally considered optimal for bone health and overall function. The average person with Parkinson’s in population studies has levels roughly 50% below that range, which underscores how common deficiency is in this group.
What Clinical Trials Have Tested
The most cited trial, a randomized double-blind study of 114 Parkinson’s patients, used 1,200 IU of vitamin D3 daily for 12 months. Patients taking vitamin D showed significantly less disease progression on the Hoehn and Yahr staging scale compared to the placebo group, whose disease worsened meaningfully over the same period. The benefit was strongest in patients with certain vitamin D receptor gene variants (FokI TT or CT genotypes), and no one in the study developed dangerously high calcium levels.
Other trials have tested 1,000 IU per day. A study of 120 patients with levodopa-induced involuntary movements found no improvement in those movements at three months on 1,000 IU, though the study was short and narrowly focused. A larger observational analysis from the NIH Exploratory Trials in Parkinson’s Disease followed 1,741 patients for three years and found no difference in overall disease scores between those taking 400 IU or more daily and those who didn’t supplement, though only 12% of participants were actually taking a standalone vitamin D supplement.
Effects on Motor Symptoms and Disease Progression
The relationship between vitamin D and Parkinson’s symptoms is more nuanced than a simple “take this and feel better.” A 2025 meta-analysis pooling six randomized controlled trials found that vitamin D supplementation did not significantly improve motor scores on the standard clinical rating scale (UPDRS Part III), walking speed, or the timed up-and-go test. In other words, vitamin D likely won’t make your movement symptoms noticeably better in the short term.
What the evidence does suggest is that vitamin D levels at baseline predict how the disease progresses over time. Lower starting levels are consistently linked to greater motor decline at follow-ups of one to three years. One study found that total disease severity scores were inversely correlated with vitamin D levels even after adjusting for age, sex, race, and supplement use. So the benefit may be more about slowing progression than reversing existing symptoms.
Interaction With Parkinson’s Medications
Vitamin D does not appear to interfere with levodopa or carbidopa, the most common Parkinson’s medications. In fact, at least one clinical case report noted the opposite: a patient’s rigidity and slowness of movement improved enough on vitamin D therapy that their levodopa dose could be reduced. Vitamin D is metabolized by the same broad family of liver enzymes (CYP enzymes) that process many drugs, but no clinically significant interactions with standard Parkinson’s medications have been identified in trials.
The Michael J. Fox Foundation lists vitamin D as one of a handful of supplements that every person with Parkinson’s should have checked and corrected if low, alongside vitamin B12, B6, and magnesium. B6 in particular can run low in people taking levodopa.
Safe Upper Limits
For adults of any age, the tolerable upper intake level set by the National Institutes of Health is 4,000 IU per day. Toxicity from vitamin D causes excess calcium in the blood, which can lead to kidney damage, soft tissue calcification, and heart rhythm problems. These effects are rare and generally only occur at sustained blood levels above 150 ng/mL (375 nmol/L), far above the 30 to 40 ng/mL target range.
If you’re significantly deficient, a doctor may prescribe a short course of higher doses (sometimes 50,000 IU weekly for several weeks) to bring levels up quickly, followed by a daily maintenance dose. A blood test for 25-hydroxyvitamin D is the only way to know your actual level and determine how much supplementation you need. Because the optimal zone for Parkinson’s patients has both a floor and a ceiling, testing matters more here than for the general population.
Practical Takeaways on Dosing
Most Parkinson’s patients in clinical trials took between 1,000 and 1,200 IU of vitamin D3 per day. That amount is safe, well within the 4,000 IU upper limit, and was enough to stabilize disease progression in the best available randomized trial. Whether you need more depends entirely on your starting blood level. Someone with a level of 15 ng/mL will need a higher dose than someone at 25 ng/mL to reach that 30 to 40 ng/mL sweet spot.
Vitamin D3 (cholecalciferol) is the preferred form over D2 (ergocalciferol) because it raises and sustains blood levels more effectively. Taking it with a meal that contains some fat improves absorption. Sun exposure contributes to vitamin D production, but most people with Parkinson’s, who tend to be older and may spend more time indoors, can’t rely on sunlight alone.